» Articles » PMID: 25872372

[CRISPR/Cas System for Genome Editing in Pluripotent Stem Cells]

Overview
Journal Tsitologiia
Specialty Cell Biology
Date 2015 Apr 16
PMID 25872372
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Genome editing systems based on site-specific nucleases became very popular for genome editing in modern bioengineering. Human pluripotent stem cells provide a unique platform for genes function study, disease modeling, and drugs testing. Consequently, technology for fast, accurate and well controlled genome manipulation is required. CRISPR/Cas (clustered regularly interspaced short palindromic repeat/CRISPR-associated) system could be employed for these purposes. This system is based on site-specific programmable nuclease Cas9. Numerous advantages of the CRISPR/Cas system and its successful application to human stem cells provide wide opportunities for genome therapy and regeneration medicine. In this publication, we describe and compare the main genome editing systems based on site-specific programmable nucleases and discuss opportunities and perspectives of the CRISPR/Cas system for application to pluripotent stem cells.

Citing Articles

Clustered regularly interspaced short palindromic repeats as an advanced treatment for Parkinson's disease.

Mehmood A, Ali W, Din Z, Song S, Sohail M, Shah W Brain Behav. 2021; 11(8):e2280.

PMID: 34291612 PMC: 8413717. DOI: 10.1002/brb3.2280.


CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson's Disease.

Safari F, Hatam G, Behbahani A, Rezaei V, Barekati-Mowahed M, Petramfar P Cell Mol Neurobiol. 2019; 40(4):477-493.

PMID: 31773362 PMC: 11448816. DOI: 10.1007/s10571-019-00761-w.